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Abstract
In a randomized clinical trial with an observation period
of 2.5 years, the differential efficacy of lithium versus car-
bamazepine was compared in 171 bipolar patients
(DSM-IV). In order to investigate the efficacy of the two
drugs in clearly defined subsamples, a series of sub-
group analyses was carried out. First, patients with a
bipolar I disorder (n = 114) were analyzed separately. In
these patients, lithium was superior to carbamazepine. In
contrast, carbamazepine was at least equally as effica-
cious as lithium in the subsample of patients with bipolar
II disorder or bipolar disorder not otherwise specified
(n = 57). In a second analysis on differential efficacy, the
whole sample was subdivided into a classical subgroup
(bipolar I patients without mood-incongruent delusions
and without comorbidity; n = 67) and a nonclassical sub-
group including all other patients (n = 104). Classical
bipolar patients had a significantly lower hospitalization
rate under lithium than under carbamazepine prophylax-
is (26 vs. 62%, p = 0.012). For the nonclassical group, a
tendency in favor of carbamazepine was found. In a third
step, we analyzed the impact of episode sequence on dif-
ferential efficacy. In a global view, the episode sequence
prior to the index episode was not correlated to differ-
ential efficacy. Our results might, however, indicate that
patients with an episode sequence of mania-depression-
free interval responded better to lithium. Besides differ-
ential efficacy, suicidal behavior and patients’ satisfac-
tion with treatment were investigated. Regarding suici-
dal behavior, a trend in favor of lithium was found. The
data on patients’ satisfaction were significantly in favor
of carbamazepine. In conclusion, lithium appears to be
superior to carbamazepine in classical bipolar cases and
might have additional impact on proneness to suicide.
The distinctly larger group of patients with nonclassical
features might profit more from carbamazepine which
seems to be well accepted by the patients. Hence, treat-
ment alternatives to lithium are desirable for the majority
of bipolar patients.
Copyright © 2000 S. Karger AG, Basel
Introduction
Since lithium first demonstrated prophylactic efficacy
in bipolar disorder, the phenomenology of the samples
investigated has changed considerably. This is partially
due to a shift from the diagnostic systems used in the
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Table 1. Monopharmacological treatment
strategies in the prophylaxis of bipolar
disorder
Substance Remarks
Efficacy established by several controlled studies
Efficacy seems to be negatively affected by
mood-incongruent delusions
rapid cycling
psychiatric comorbidity
secondary affective disorders
Efficacy seems to be positively influenced by
a typical clinical picture
an episode sequence of MDI1
Some evidence from open studies of antisuicidal efficacy
Carbamazepine Evidence of efficacy from controlled studies
Seems to have a broader spectrum of efficacy than lithium
Valproate Some evidence of efficacy from open studies and from clinical experience
Might be especially helpful in rapid cycling
Lamotrigine? Regarding efficacy of these substances, there is only poor evidence
Gabapentine? from a few case reports and open studies, 
Topiramate? Lamotrigine might be helpful in treating bipolar depression
Nimodipine? Nimodipine might be helpful in ultra rapid cycling bipolar disorder
Clozapine? Clozapine might be helpful in schizoaffective disorders
Olanzapine?
1 MDI = Mania-depression-free interval.
1960s and 1970s to recent diagnostic manuals such as
DSM-IV and ICD-10. The diagnostic criteria for affective
disorders have become broader and more differentiated
over the last decades. For example, patients who present
both manic and schizophrenic symptoms are more readily
ascribed to the bipolar disorders as compared to the time
when lithium was introduced as prophylactic agent [1–3].
This trend towards the broadening and subclassifying of
diagnostic categories is fostered by modern research
which pays more attention to mixed states, rapid cycling
and subsyndromal affective states [3–8]. In consequence,
the spectrum of patients diagnosed as bipolar has become
more heterogeneous over time. It is unclear whether lithi-
um, which was proven to be efficacious for quite a specific
disorder covers the whole spectrum of bipolarity. There is
some evidence that this is not the case, and that alterna-
tive treatments are needed [2, 9–11].
The first generation of alternative treatments, the anti-
convulsants carbamazepine and valproate, has shown
beneficial effects in many patients and is well established
in the prophylaxis of lithium-nonresponsive bipolar ill-
ness [12–17]. Initial data also support prophylactic effica-
cy of further pharmacological strategies including lamo-
trigine, gabapentine, nimodipine and olanzapine [18–25]
(table 1). Regarding the use of these mood stabilizers, lit-
tle is known about the prediction of response to different
treatment strategies [26] (table 1). First, only a few clinical
features for differential indication have been found. Sec-
ond, the evidence on differential indication is mainly
based on uncontrolled studies and case reports that do not
allow for definite conclusions. Hence, knowledge on dif-
ferential efficacy is to be considered as preliminary in
most cases and awaits confirmation in prospective ran-
domized clinical trials.
One of the randomized studies on differential efficacy
of mood-stabilizers is the Multicenter Study of Long-
Term Treatment of Affective and Schizoaffective Psy-
choses (MAP study). The relevant results of this study
regarding efficacy of lithium versus carbamazepine in
clearly defined subgroups are summarized in the follow-
ing text. Data on differential efficacy are supplemented by
evaluation of suicidal behavior and patients’ satisfaction
with lithium and carbamazepine. Patients’ satisfaction
with a treatment is a crucial issue in compliance, and non-
compliance is the limiting factor for efficacy in a major
part of the patients [27, 28].
Bipolar
n
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Subjects and Methods
The MAP study group comprises the psychiatric hospitals of 9
universities in Germany (Aachen, Berlin, Düsseldorf, Heidelberg,
Lübeck, München, Münster, Tübingen and Würzburg). In these cen-
ters, patients with an affective or schizoaffective episode were
Table 2. Correspondence of diagnoses in DSM-III-R and DSM-IV
DSM-III-R DSM-IV
corresponds to
→
Bipolar I
Bipolar NOS1 corresponds to
→  Bipolar IIBipolar NOS
1 NOS = Not otherwise specified.
Table 3. Demographic and clinical characteristics at study begin-
ning
Carbamazepine Lithium
85 86
Sex, % female 58 55
Age, mean years B SD 39B13 41B13
Marital status, %
Never married 33 31
Married 48 52
Separated/divorced 17 16
Widowed 2 0
Years of Education, %
^9 (elementary school) 52 47
10–12 (secondary school) 17 20
613 (graduate) 32 34
Age at onset, mean years B SD 31B12 32B12
Suicide attempts, %
None 63 58
1 26 30
2 or more 11 12
Episodes of illness (including index episode), %
2 21 10
3–10 70 76
11 or more 8 14
Hospitalizations (including index episode), %
1–2 51 52
3–10 48 48
11 or more 1 0
GAS score at study onset
mean B SD 79B10 79B10
None of the differences is significant (using Fisher’s exact test, the
¯2 test and the Wilcoxon test, respectively.
screened during hospitalization and entered the study if they fulfilled
the following criteria: (1) current episode of an affective or schizoaf-
fective disorder according to ICD-9 (296.1–296.4, 296.7); (2) at least
one additional episode during the last 5 years (unipolar depression),
4 years (bipolar disorder), 3 years (schizoaffective disorder); (3) no
prophylactic treatment immediately before the current episode;
(4) no diagnosis of alcohol or drug abuse (current); (5) no contraindi-
cation against one of the study medications; (6) age between 18 and
65 years, and (7) informed consent.
As we intended to study the efficacy of maintenance (not contin-
uation) treatment [29], patients entered the study after recovery from
the index episode (Global Assessment Scale, GAS, 170 for at least 2
weeks within 6 months after discharge [30]). Bipolar and schizoaffec-
tive patients received lithium or carbamazepine as study medication.
After randomization to prophylactic treatment, the study patients
were treated in an outpatient setting during a maintenance phase of
2.5 years. Psychotropic comedication was avoided during the main-
tenance phase. However, if concomitant medication was judged to be
inevitable, it was accepted and documented. A detailed description
of the study design is given in Greil et al. [31, 32]. Following a poly-
diagnostic approach, patients were diagnosed not only according to
ICD-9 but also according to DSM-III-R using the Structured Clinical
Interview of Mental Disorders and according to RDC [33]. This
paper summarizes the results on bipolar patients according to DSM-
III-R using DSM-IV terminology. The exact correspondence between
these diagnostic systems is given in table 2.
To make sure that the results do not depend on the specific defini-
tion of a treatment failure, different failure criteria were formulated
for statistical analyses (for details see Greil et al. [32]): (1) hospitaliza-
tion, (2) recurrence, (3) recurrence and/or concomitant psychotropic
medication (antidepressants and/or neuroleptics) for at least 6
months, (4) recurrence and/or concomitant psychotropic medication
and/or side effects prompting discontinuation of treatment and
(5) recurrence and/or subclinical recurrence. In the present paper,
data are presented with respect to hospitalization, but we always
indicate whether the results depend on the way efficacy has been ana-
lyzed. In this case, additional data regarding the other outcome crite-
ria are provided.
Statistical Analyses
The statistical evaluation of the failure rates, dropouts and side
effects was done by Fisher’s exact test. The association between treat-
ment outcome and the number of nonclassical diagnostic features
was evaluated using Mantel-Haenszel statistics [34]. These tests are
based on the failure rates of the patients who completed the study
according to protocol (ATP). ATP analyses were corroborated by
Kaplan-Meier estimates of the survival curves based on intention-
to-treat data [35]. Survivor functions were tested for equality using
Tarone-Ware statistics [36].
Results
Study Patients
Of the 171 patients with a diagnosis of bipolar disorder
(DSM-IV), 86 had been randomized to lithium and 85 to
carbamazepine. No significant differences between the
treatment groups were found in clinical and sociodemo-
Treatment-related reasons
Hospitalization
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graphic variables including sex, age, family history of
affective disorders, age at onset of illness, number of pre-
vious episodes, GAS score [30] at study onset and acute
treatment of the index episode (table 3).
In the acute treatment of the index episode, lithium
and carbamazepine played only a minor role (9% of the
patients treated with lithium and 8% treated with carba-
mazepine). The average dose during the maintenance
phase (between month 2 and study termination) was 26.8
B 6.76 mmol/day for lithium (serum level 0.61 B 0.12
mmol/l) and 635 B 190 mg/day for carbamazepine (se-
rum level 6.12 B 1.27 Ìg/ml).
Dropout Patients
As compared to lithium, more patients treated with
carbamazepine dropped out of the study before having a
recurrence (12 vs. 28; p = 0.004, Fisher’s exact test). Rea-
sons for noncompletion are summarized in table 4.
Bipolar I versus Bipolar II/Not Otherwise Specified
In a first subgroup analysis, efficacy of lithium and car-
bamazepine was compared in patients with bipolar I and
in patients with bipolar II or bipolar disorder not other-
wise specified (NOS), respectively. In bipolar I patients,
the failure rate was about 50% higher in the carbamaze-
pine group for all failure criteria (table 5). This result is
significant for the broader failure criteria 3–5, which are
very sensitive in detecting differences between treatment
strategies [37]. These results have been substantiated by
survival analyses (not shown). All data consistently sug-
gest that lithium was clearly more efficacious than carba-
mazepine in the maintenance treatment of bipolar I
patients.
Regarding bipolar II/NOS patients, the results are far
less conclusive for several reasons. As can be seen from
table 6, the results on comparative efficacy of lithium and
carbamazepine are substantially influenced by the choice
of the outcome criterion. It is also difficult to attribute the
results to a precise diagnostic group as the subsample of
bipolar II/NOS patients is quite heterogeneous compris-
Table 4. Reasons for noncompletion (dropouts)
Reasons for
noncompletion
Carbamazepine
(n = 85)
Lithium
(n = 86)
Unwanted side effects1 8 3
Inefficacy of therapy2 2 0
Protocol violations
Contraindication3 3 0
Other reasons4 15 9
n 28 12
1 Under carbamazepine: exanthema, swollen lymphoma and head-
ache (1 patient), allergy and rash (1), generalized eczema (1), allergic
skin reaction (1), hepatopathy (1), swollen lymphoma and diarrhea
(1), exanthema. Under lithium: vertigo, nausea and headache (1),
acne and weight gain (1), disturbances of potency (1).
2 Discontinuation by the physician because of long-term need of
concomitant medication.
3 Pregnancy (2 patients) and change of diagnosis (1).
4 This category comprises patients in whom noncompletion
seemed not to be related to the treatment, e.g. external circumstances
or decision against further treatment without clear reasons.
Table 5. Failure rates for lithium and carbamazepine in bipolar I patients
Failure criterion Carbamazepine
(n = 56)
failure rates, %
Lithium
(n = 58)
failure rates, %
Relative
risk
p
55 37 1.49 0.09
Recurrence 59 40 1.49 0.09
Recurrence and/or concomitant medication 67 44 1.52 0.04
Recurrence and/or concomitant medication
and/or side effects 71 46 1.54 0.01
Recurrence and/or subclinical recurrence 71 48 1.48 0.04
The percentages refer to completers according to protocol (ATP). The exact number of completers depends on the
failure criterion (for details see Greil et al. [38, 39]). The relative risk is the risk for a treatment failure under carbama-
zepine divided by the risk for a treatment failure under lithium. Significances were determined by Fisher’s exact
test.
Hospitalization
Depression
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Table 6. Failure rates for lithium and carbamazepine in bipolar II/NOS patients
Failure criterion Carbamazepine (n = 29)
failure rates, %
bipolar
II (n = 14)
bipolar
NOS (n = 15)
Lithium (n = 28)
failure rates, %
bipolar
II (n = 9)
bipolar
NOS (n = 19)
Relative
risk
p
14 7 0 37 0.50 0.29
Recurrence 28 7 11 37 0.73 0.73
Recurrence and/or concomitant medication 36 33 33 37 1.11 1.00
Recurrence and/or concomitant medication
and/or side effects 50 33 33 47 0.91 1.00
Recurrence and/or subclinical recurrence 50 27 78 53 0.78 0.35
The percentages refer to completers according to protocol (ATP). The exact number of completers depends on the failure criterion (for
details see Greil et al. [38, 39]). The distinction between bipolar I and bipolar NOS was made according to RDC criteria [33]. The relative risk
is the risk for a treatment failure under carbamazepine divided by the risk for a treatment failure under lithium. The relative risk refers to the
entire subsample of bipolar II/NOS patients. Significances were determined by Fisher’s exact test.
ing bipolar II patients and different types of bipolar
patients not otherwise specified. Finally, the case num-
bers are too small to allow for definite conclusions.
When we cautiously try to summarize the data on the
bipolar II/NOS patients, it appears that in contrast to
bipolar I patients, carbamazepine was at least equally as
efficacious as lithium. With respect to hospitalization and
recurrences as failure criteria, a tendency in favor of car-
bamazepine might be attributed to the bipolar NOS sub-
sample (failure rate 7 vs. 37%). This attribution is, how-
ever, not that clear for the other failure criteria (table 6).
The Impact of Nonclassical Features
Besides the distinction between bipolar I and bipolar
II/NOS, further subclassification was done in order to test
the hypothesis that lithium is selectively efficacious in
classical bipolar patients. The entire sample of bipolar
patients (DSM-IV) was subdivided into a classical sub-
group (bipolar I patients without mood-incongruent delu-
sions and without psychiatric comorbidity; n = 67) and a
nonclassical subgroup including all other patients (n =
104). Classical bipolar patients had a lower hospitaliza-
tion rate under lithium than under carbamazepine pro-
phylaxis (26 vs. 62%, p = 0.012). For the nonclassical
group, a tendency in favor of carbamazepine was found
(44 vs. 31%, p = 0.34).
As can be seen from figure 1, there was a positive asso-
ciation in the lithium group between hospitalization rate
and the number of nonclassical features (bipolar II/NOS,
mood-incongruent delusions, comorbidity; p = 0.035).
For carbamazepine, this association was negative (p =
Table 7. Hospitalization rate (ATP) in relation to episode sequence
Episode sequence immediately
before the index episode
Carbamazepine Lithium
40% (8/20) 41% (9/22)
Mania 25% (2/8) 39% (7/18)
MDI 75% (3/4) 0% (0/7)
DMI 0% (0/6) 11% (1/9)
Other 61% (11/18) 53% (10/19)
0.033). When other outcome criteria such as recurrence or
subclinical recurrence are applied, the results regarding
the negative relationship between nonclassical features
and lithium response were fully confirmed with p values
ranging from 0.002 to 0.07. Regarding carbamazepine
response, the relation was only confirmed as a trend (p
values ranging from 0.07 to 0.27). Case numbers are too
small to determine the exact contribution of each of these
nonclassical criteria (for details see Greil et al. [38]).
The Impact of Episode Sequence
In order to investigate the impact of the episode
sequence on differential efficacy, a standardized rating of
the patients’ history was used. At study entry, the episode
immediately before the index episode has been catego-
rized as ‘mania’, ‘depression’, ‘MDI’ (sequence mania-
depression-free interval), ‘DMI’ (sequence depression-
mania-free interval) or ‘other’ (e.g. mixed, schizoaffective,
continuous cycling).
Suicide during study period
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Fig. 1. Failure rates (hospitalization).
Table 8. Suicidal behavior in patients randomized to lithium or carbamazepine
Bipolar (DSM-IV)
(n = 171)
lithium carbamazepine
Bipolar or schizoaffective
(ICD-9) (n = 285)1
lithium carbamazepine
0 0 0 1
Attempted suicide during study period 0 4 0 5
1 285 = 171 (bipolar according to DSM-IV) + 114 (bipolar or schizoaffective according to ICD-9, but not bipolar
according to DSM-IV).
In a global view, the episode sequence prior to the
index episode was not correlated to differential efficacy
(total ¯2  = 10.2, d.f. = 8; table 7). Our results might, how-
ever, indicate that patients with an episode sequence of
MDI had a lower hospitalization rate under lithium as
compared to carbamazepine (0 vs. 75%; table 7). Similar
results are obtained when the other outcome criteria are
applied. From a nosological point of view, it is also nota-
ble that this episode sequence (MDI) was significantly
correlated to the absence of nonclassical features (Ê =
0.23, p = 0.0059).
Suicidal Behavior
In the sample of patients with a diagnosis of bipolar
disorder (DSM-IV), 4 suicide attempts were observed
during the treatment period. These patients were on car-
bamazepine at the time they attempted suicide (table 8).
Considering all patients who had been randomized to lith-
ium or carbamazepine (i.e. all bipolar and schizoaffective
patients according to ICD-9; see Subjects and Methods), 1
additional suicide attempt and 1 completed suicide were
observed. All of the 6 suicides occurred in the carbamaze-
pine group (table 8). These data refer to the controlled
treatment period. When additional data from the time
before and after the controlled observation period is taken
into account, 3 more suicidal acts were observed (not
shown). Again, all 3 patients were under carbamazepine
and none under lithium at the time they committed sui-
cide [40].
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Side Effects and Patients’ Satisfaction
Side effects leading to discontinuation were more fre-
quent under carbamazepine as compared to lithium (8 vs.
3, n.s.; table 4). The most frequently observed side effect
leading to carbamazepine-discontinuation was allergic
skin reactions at the beginning of the treatment (for
details see Greil et al. [41, 42]).
Side effects were also analyzed after exclusion of those
occurring at the beginning of the treatment period. In con-
trast to the data regarding initial side effects leading to
discontinuation, global ratings of the severity of side
effects after 1, 2 and 2.5 years were all in favor of carba-
mazepine. At the end of study period, at least slight side
effects were reported by 55% of the patients treated with
lithium as compared to 24% of the patients under carba-
mazepine (p = 0.0006).
The satisfaction with treatment in general at the end of
the observation period was higher in the carbamazepine
group (86 vs. 79 on a 100-mm visual analogue scale, p =
0.026, Wilcoxon test).
Discussion
Patients with a classical presentation of the manic-
depressive illness were more likely to respond to prophy-
lactic lithium as compared to carbamazepine. In our
interpretation, a classical manic-depressive patient has a
diagnosis of bipolar I disorder without mood-incongruent
features and without psychiatric comorbidity. The high
response rates of lithium in these patients are also sup-
ported by the fact that this treatment was very efficacious
in patients with the classical episode sequence of MDI.
The less a patient resembled the classical type, the higher
was the relative efficacy of carbamazepine. This is a
robust finding that is largely independent of the failure
criterion investigated and the statistical methodology ap-
plied.
The data presented in this paper stem from a random-
ized prospective study. The recruitment process was care-
fully documented in order to investigate whether the
study sample is representative. When comparing the pa-
tients who participated in the study to those who fulfilled
the inclusion criteria without entering the treatment
phase, no major differences regarding clinical and socio-
demographic variables were found [31, 38]. Hence, we
assume that the enrollment did not result in a substantial
bias. Similarly, the randomization is considered to be suc-
cessful as no significant differences between the treatment
groups were found regarding these clinical and sociode-
mographic variables. Care was taken to avoid contamina-
tion of the results due to withdrawal effects and to study
efficacy of maintenance (not continuation) treatment.
With respect to episode frequency, the observation period
of 2.5 years was long enough to achieve adequate statisti-
cal power.
The study was kept nonblind on purpose. It would
have been difficult to carry out a blind study over 2.5
years with two substances that present a clearly different
side effect profile. In the study on lithium and carbamaze-
pine of Watkins et al. [43] blindness could not be kept,
and there has been serious doubt in the validity of the
double-blind design in long-term trials [44]. In our study,
it cannot be excluded that because of the more recent
introduction of carbamazepine as a mood stabilizer, the
physicians were less confident in the efficacy of carbama-
zepine as compared to lithium. This might have led them
to discontinue treatment with carbamazepine earlier than
a treatment with lithium. However, reasons for dropout
appear quite appropriate and do not seem to be related to
an excessive cautiousness of the participating psychia-
trists [41, 42]. Nevertheless, the present results might be
biased by the clinical experience of the physicians.
The data presented on the differential efficacy of lithi-
um and carbamazepine are in line with several observa-
tions on the response to prophylactic lithium published
over the last decades. As early as 1967 Baastrup and
Schou [45] noted that ‘lithium is highly effective in purely
affective disorders’ and have found ‘a considerable ten-
dency to relapse ... when the picture shows atypical fea-
tures’. In Baastrup and Schou [45], atypical features
mainly refer to mood-incongruent delusions. The nega-
tive influence of this feature on lithium response has been
confirmed in several retrospective studies [46, 47]. Simi-
larly, the negative association between psychiatric comor-
bidity [47, 48] and lithium response and the positive
influence of an episode sequence MDI [49–51] have been
found previously. Further clinical features that have been
reported to be negative predictors for lithium prophylaxis
are rapid cycling and mixed states [52]. In our study, rap-
id cycling could not be investigated as a further predictor
of differential response. Due to the stabilization period of
several months after discharge before entry into the study,
these patients were excluded according to the study proto-
col. Corresponding to the strict criteria of DSM-IV, a
mixed state in the index episode was diagnosed in only 7%
(n = 8) of the patients. Hence, mixed states were only
investigated in additional analyses which support the con-
clusion that lithium is more efficacious than carbamaze-
pine in typical manic-depressive patients (for details see
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Greil et al. [38]). The observed efficacy of lithium versus
carbamazepine does not seem to be caused by the en-
zyme-inducing properties (leading to reduced blood levels
of comedication) of the latter drug, since similar results
have been obtained in patients with and without concom-
itant psychotropic medication [39].
The majority of the patients were classified as nonclas-
sical. Besides the broadening of diagnostic criteria, this
might be attributed to a selection bias that results from the
fact that the patients were recruited in university hospi-
tals. Patients with more atypical, treatment-unresponsive
illness may be overrepresented in most research centers
[8, 53]. In general, the use of lithium is limited by its nar-
row therapeutic range and its disturbing side effects [54,
55]. Furthermore, affective episodes may reappear in
patients after several years of an apparently successful
lithium prophylaxis [56]. Hence, treatment alternatives to
lithium are desirable in a high percentage of patients with
bipolar disorder.
The large nonclassical subgroup might be of special
interest in designing future clinical trials investigating the
efficacy of newer mood stabilizers such as valproate or
lamotrigine. Valproate has shown beneficial effects in the
prophylaxis of rapid-cycling [14, 15, 57, 58] and ultra-rap-
id-cycling bipolar disorders [59] as well as in the acute treat-
ment of mania and mixed states [60–62]. Lamotrigine may
be especially helpful in the prophylaxis of rapid cycling and
in the acute treatment of bipolar depression [18, 63]. Fur-
ther studies on the efficacy of anticonvulsants in clearly
defined subgroups of bipolar patients would be beneficial
for the development of treatment algorithms and might
also stimulate nosological and biochemical research.
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